NAPS2 Polysomnogram Core

摘要：NAPS2多导睡眠图(PSG) 快速眼动(REM)睡眠行为障碍(RBD)以做梦行为为特征， 多导睡眠图(PSG)的神经生理特征是无张力的快速眼动睡眠(RSWA)。RBD 通常代表一种前驱综合征，越来越多的证据表明RSWA可能是一种 突触核病相关病理的生物标志物：RSWA随着时间的推移而增加，预测表型转化为临床 突触核病，并与突触核蛋白病理的临床措施相关。然而，由于缺乏数据， 从前瞻性的多中心研究中，还没有确定的RSWA值可以用作 生物标志物。治疗RBD的北美前驱综合征(NAP)联盟是 成立于2018年，支持RBD的多中心研究，长期目标是促进发展 在RBD进行的神经保护临床试验。我们成功地从10个地点收集了回溯性PSG数据 午睡网站。这些初步数据证明了分析RSWA和其他神经生理学的可行性 在PSG期间跨多个站点和平台获取的信号。在NAP阶段2或NAPS2中，我们将在 我们目前有大量RBD参与者，并将从&gt；300 RBD收集研究级PSG数据 参与者两次，相隔两年，一次来自匹配对照组的参与者。NAPS2 PSG核心将 监督PSG数据的收集、分析和分发，总体目标是将RSWA作为 用于未来临床试验的共核病生物标记物。NAPS2 PSG核心将标准化 并协调跨NAPS2站点的PSG数据收集。PSG核心将量化REM睡眠 使用各种方法治疗肌张力障碍(RSWA)，并确定RSWA的个体内进展程度 随着时间的推移。PSG核心将向NAPS2项目提供关键的RSWA指标，以评估RSWA作为 预测表型转化和追踪突触核蛋白相关病理进展的生物标记物。所有PSG数据都将 通过NIH赞助的国家睡眠研究资源(NSRR)公开分享，这是一个全国性的 基于睡眠的电生理数据的储存库。我们将与NAPS2数据管理和 统计(DMS)核心开发信号处理和新的机器学习方法，应用于 在PSG期间记录脑电和其他神经生理信号。巴黎圣日耳曼核心将 探索以家庭为基础的PSG非实验室替代方法的可行性和可靠性。NAPS2 PSG Core将使RSWA成为前驱联体核病的生物标志物，促进 研究PSG派生的神经生理信号，推进PSG数据的技术改进 收集和分析。

ABSTRACT: NAPS2 POLYSOMNOGRAM (PSG) CORE Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by dream enactment behavior, and its neurophysiologic signature during polysomnography (PSG) is REM sleep without atonia (RSWA). RBD usually represents a prodromal synucleinopathy, and increasing evidence suggests RSWA may serve as a biomarker of synucleinopathy-related pathology: RSWA increases over time, predicts phenoconversion to overt synucleinopathy, and correlates with clinical measures of synuclein pathology. However, due to lack of data from prospective, multi-center studies, there are no established RSWA values that can be used as a biomarker. The North American Prodromal Synucleinopathy (NAPS) Consortium for RBD was established in 2018 to enable multicenter research in RBD with the long-term goal of promoting development of neuroprotective clinical trials in RBD. We successfully collected retrospective PSG data from across 10 NAPS Sites. These preliminary data demonstrate feasibility of analyzing RSWA and other neurophysiologic signals acquired during PSG across multiple sites and platforms. In NAPS Stage 2, or NAPS2, we will build on our current large cohort of participants with RBD, and will collect research-grade PSG data from >300 RBD participants twice, two years apart, and once from matched Control participants. The NAPS2 PSG Core will oversee collection, analysis, and distribution of PSG data, with the overall goal of developing RSWA as a biomarker for synucleinopathies for application in future clinical trials. The NAPS2 PSG Core will standardize and harmonize PSG data collection across NAPS2 Sites. The PSG Core will quantify REM sleep without atonia (RSWA) using a variety of methods, and determine the degree of within-individual progression in RSWA over time. The PSG Core will provide key RSWA metrics to the NAPS2 Project for assessment of RSWA as a biomarker to predict phenoconversion and track progression of synuclein-related pathology. All PSG data will be shared publicly through the NIH-sponsored National Sleep Research Resource (NSRR), a national repository of sleep-based electrophysiologic data. We will coordinate with the NAPS2 Data Management and Statistical (DMS) Core to develop signal processing and novel machine learning methods for application to electroencephalography and other neurophysiological signals recorded during PSG. The PSG Core will explore the feasibility and reliability of alternative, non-laboratory methods for home-based PSG. The NAPS2 PSG Core will enable development of RSWA as a biomarker for prodromal synucleinopathies, promote research with PSG-derived neurophysiologic signals, and advance technological improvements in PSG data collection and analysis.